title: Augmentation of murine lymphokine-activated killer cell cytotoxicity by beta-cyclodextrin-benzaldehyde.
abstract: We investigated the effect of beta-cyclodextrin-benzaldehyde (CDBA) on lymphokine-activated killer (LAK) cell activity of spleen cells from normal or RCT(+)H-2(+)-sarcoma-bearing C3H/He mice. CDBA augmented the induction of LAK cytotoxicity in vitro against RCT(+)H-2+ tumor cells by IL-2, whereas the culture with CDBA alone did not. In a LAK cytotoxicity assay in vitro, the augmentative effect of CDBA was strongly exerted against spleen cells originating from 2-week-tumor-bearing mice, rather than those from normal mice or mice that had born tumors for 5 weeks. Such an augmentative effect was not observed against other tumor cells (YAC-1, D-6, Colon-26 and EL-4 cells) non-specifically. When the intravenous adoptive transfer of LAK cells was carried out in the mice, LAK cells from tumor-bearing mice induced by combined culture with interleukin-2 (IL-2) and CDBA markedly inhibited the pulmonary metastases of RCT(+)H-2+ tumor, while neither LAK cells from the same tumor-bearing mice induced by only IL-2 nor those from normal mice inhibited the pulmonary metastasis. The majority of LAK cells induced either by IL-2 plus CDBA or by IL-2 alone were found to be Thy1.2+ and asialoGM1+ cells by flow-cytometric analysis, but no obvious phenotypical difference was observed between them. However, the most significant effect of CDBA might be the maintenance of the Lyt-2+ cell level in the spleen cells from tumor-bearing mice. These results suggested that the costimulation of spleen cells with IL-2 and CDBA might induce cytotoxic T cells specific for syngeneic tumor cells.
authors.affiliation: Second Department of Surgery, Toyama Medical and Pharmaceutical University, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Kuroki
authors.forename: H
authors.initials: H
authors.lastname: Ochiai
authors.forename: M
authors.initials: M
authors.lastname: Kurokawa
authors.forename: S
authors.initials: S
authors.lastname: Niwayama
authors.forename: C
authors.initials: C
authors.lastname: Kishimoto
authors.forename: K
authors.initials: K
authors.lastname: Tazawa
authors.forename: M
authors.initials: M
authors.lastname: Fujimaki
mesh_terms: D000818:Animals; D001547:Benzaldehydes / Q000494:pharmacology*; D003505:Cyclodextrins / Q000494:pharmacology*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D004357:Drug Synergism; D005434:Flow Cytometry; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000276:immunology*; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D012509:Sarcoma / Q000556:secondary / Q000628:therapy; D047392:beta-Cyclodextrins
chemical_list: D001547:Benzaldehydes; D003505:Cyclodextrins; D007376:Interleukin-2; D047392:beta-Cyclodextrins; C050452:beta-cyclodextrin-benzaldehyde; C031215:betadex